Avalon Globocare Corp - ESG Rating & Company Profile powered by AI
This ESG rating covers 17 UN SDGs including: 'Clean Water & Sanitation', 'Responsible Production & Consumption' and 'Peace, Justice & Strong Institutions'. Detailed Sustainability analysis of Avalon Globocare Corp are reached by registering for free. The page contains a zero-cost Sustainability analysis for Avalon Globocare Corp.
Avalon Globocare Corp in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 8.0, social score of 4.8 and governance score of 8.0.
6.9
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
25 | Rive Medical Inc | 7.1 | High |
30 | Actelion Ltd | 7.0 | High |
31 | Avalon Globocare Corp | 6.9 | High |
31 | Precipio Inc | 6.9 | High |
33 | FYI Resources Ltd | 6.8 | High |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Avalon Globocare Corp have an accelerator or VC vehicle to help deliver innovation?
Does Avalon Globocare Corp disclose current and historical energy intensity?
Does Avalon Globocare Corp report the average age of the workforce?
Does Avalon Globocare Corp reference operational or capital allocation in relation to climate change?
Does Avalon Globocare Corp disclose its ethnicity pay gap?
Does Avalon Globocare Corp disclose cybersecurity risks?
Does Avalon Globocare Corp offer flexible work?
Does Avalon Globocare Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Avalon Globocare Corp disclose the number of employees in R&D functions?
Does Avalon Globocare Corp conduct supply chain audits?
Does Avalon Globocare Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Avalon Globocare Corp conduct 360 degree staff reviews?
Does Avalon Globocare Corp disclose the individual responsible for D&I?
Does Avalon Globocare Corp disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Avalon Globocare Corp disclose current and / or historical scope 2 emissions?
Does Avalon Globocare Corp disclose water use targets?
Does Avalon Globocare Corp have careers partnerships with academic institutions?
Did Avalon Globocare Corp have a product recall in the last two years?
Does Avalon Globocare Corp disclose incidents of discrimination?
Does Avalon Globocare Corp allow for Work Councils/Collective Agreements to be formed?
Has Avalon Globocare Corp issued a profit warning in the past 24 months?
Does Avalon Globocare Corp disclose parental leave metrics?
Does Avalon Globocare Corp disclose climate scenario or pathway analysis?
Does Avalon Globocare Corp disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Avalon Globocare Corp disclose the pay ratio of women to men?
Does Avalon Globocare Corp support suppliers with sustainability related research and development?
Does Avalon Globocare Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Avalon Globocare Corp reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Avalon Globocare Corp involved in embryonic stem cell research?
Does Avalon Globocare Corp disclose GHG and Air Emissions intensity?
Does Avalon Globocare Corp disclose its waste policy?
Does Avalon Globocare Corp report according to TCFD requirements?
Does Avalon Globocare Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Avalon Globocare Corp disclose energy use targets?
Does Avalon Globocare Corp disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Avalon Globocare Corp have a policy relating to cyber security?
Have a different question?
Potential Risks for Avalon Globocare Corp
These potential risks are based on the size, segment and geographies of the company.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.